Catalyst Event
Tempus AI Inc (TEM) · Other
From Akros U.S. AI Software TOP4 Plus Index (AUAIS4P)
5/29/2026, 12:00:00 AM
Tempus announced FDA approval on 2026-05-29 for a tumor-only indication for its xT CDx platform, enabling migration of its DNA solid tumor portfolio; shares rose about 3.5% on the news.
Korean Translation
2026-05-29 Tempus가 xT CDx 플랫폼의 종양 단독 적응증에 대한 FDA 승인을 발표해 DNA 고형암 포트폴리오 이전이 가능해졌으며, 해당 소식에 주가가 약 3.5% 상승함.
Related Recent Events
Fastly Inc (FSLY) · Earnings Release
Fastly is scheduled to report its Q2 2026 financial results after market close on August 5, 2026, with revenue guidance of $170M–$176M and non-GAAP EPS of $0.05–$0.08; high importance is estimated based on historical earnings volatility scheduled.
8/5/2026, 12:00:00 AM
ServiceNow Inc (NOW) · Earnings Release
Next quarterly earnings for Q2 2026 are scheduled to be released on July 22, 2026, scheduled
7/22/2026, 12:00:00 AM
SALESFORCE INC (CRM) · Other
Quarterly cash dividend of $0.44 per share with an ex-dividend date of June 11, 2026; low importance as dividends typically have minimal price impact scheduled.
6/11/2026, 12:00:00 AM
Oracle Corp (ORCL) · Earnings Release
Q4 2026 earnings release scheduled. Analysts forecast strong performance in the cloud computing segment, driven by AI demand, with an expected EPS of $1.96 on $19.1 billion in revenue. High importance due to potential for significant price impact forecasted.
6/10/2026, 12:00:00 AM
ServiceNow Inc (NOW) · Other
Announced an expanded partnership with Cognizant on June 4, 2026, to integrate Cognizant's Neuro AI Trust platform with the ServiceNow AI Control Tower, aiming to provide continuous, automated AI governance and assurance for enterprises; positive impact expected from AI service expansion.
6/4/2026, 12:00:00 AM
Innodata Inc (INOD) · Other
The 2026 Annual Meeting of Shareholders was held virtually. This routine administrative event is estimated to have a >1% price impact, scheduled.
6/4/2026, 12:00:00 AM